Halozyme completes $1.5B 1.50% convertible notes due 2033; repurchases existing notes

HALOZYME THERAPEUTICS, INC.

Issued $1.5B aggregate 1.50% Convertible Senior Notes due 2033; net proceeds ~$1,471.1M.
Repurchasing $151.7M of 0.25% 2027 Notes and $220M of 1.00% 2028 Notes for ~$217M and $435.5M incl. interest.
Spent $187.5M on capped call transactions; cap price initially $208.39/share (~90% premium).
Initial conversion price ~$139.84/share (7.1509 shares per $1,000 principal).
Remaining proceeds for general corporate purposes, potential acquisitions, and future note repurchases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.